Application of Immune Checkpoint Inhibitors in Advanced Melanoma

Authors

  • Naran Zhang
  • Yule Zheng

DOI:

https://doi.org/10.54097/k3gd9f44

Keywords:

Immune Checkpoint Inhibitors, advanced melanoma, CTLA-4, PD-1, irAEs.

Abstract

The advent of ICIs has significantly improved outcomes for many types of cancer treatment, including advanced melanoma that cannot be respected. Among melanoma patients, there is clear evidence that Ipilimumab, the first monoclonal antibody approved for CTLA-4 targeting, as well as nivolumab and pembrolizumab, which concentrate on PD-1, have led to increased overall survival. Combination therapy with other therapies shows better efficacy with ICI compared to monotherapy (e.g., a combination of CTLA-4 and PD-1 inhibitors). This article will explore recent research on the therapies of advanced melanoma, investigate the pathways of CTLA-4 and PD-1/PD-L1 and their application as single therapy or combination with other therapies such as PD-1 drugs, in addition to other therapeutic methods, and the current application of TCM treatment. In addition, this review will discuss drug resistance to ICI treatment and explore potential biomarkers associated with ICI response in advanced melanoma patients and future prospects for ICI treatment.

Downloads

Download data is not yet available.

References

Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P., & Barsouk, A. (2021). Epidemiology of Melanoma. Medical sciences (Basel, Switzerland), 9 (4), 63.

Sharpe, A. H., & Freeman, G. J. (2002). The B7 – CD28 superfamily. Nature Reviews Immunology, 2 (2), Article 2.

Pardoll, D. M. (2012). The blockade ofimmune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12 (4), Article 4.

Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E.,Knutson, K. L., Chumsri, S., & Lou, Y. (2018). Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal of hematology & oncology, 11, 1 - 20.

Hodi, F. S., O’Day, S. J., McDermott, D.F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J. M., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., … Urba, W. J. (2010). Improved Survival with Ipilimumab inPatients with Metastatic Melanoma. New England Journal of Medicine, 363 (8), 711 – 723.

Ribas, A., Kefford, R., Marshall, M. A., Punt, C. J., Haanen, J. B., Marmol, M., Garbe, C., Gogas, H., Schachter, J., Linette, G., Lorigan, P., Kendra, K. L., Maio, M., Trefzer, U., Smylie, M., McArthur, G. A., Dreno, B., Nathan, P. D., Mackiewicz, J., Kirkwood, J. M., … Hauschild, A. (2013). Phase III randomized clinical trial comparing tremelimumab withstandard-of-care chemotherapy in patients with advanced melanoma. Journal ofclinical oncology: official journal of the American Society of Clinical Oncology, 31 (5), 616 – 622.

Larkin, J., Minor, D., D'Angelo, S., Neyns, B., Smylie, M., Miller Jr, W. H., ... & Weber, J. (2018). Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. Journal of clinical oncology, 36 (4), 383.

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C. U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., …Ribas, A. (2015). Pembrolizumab versus Ipilimumab in Advanced Melanoma. NewEngland Journal of Medicine, 372 (26), 2521 – 2532.

Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., ... & Daud, A. (2015). Pembrolizumabversusinvestigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomized, controlled, phase 2 trial. The lancet oncology, 16 (8), 908 - 918.

Postow, M.A.; Chesney, J.; Pavlick, A.C.; Robert, C.; Grossmann, K.; McDermott, D.; Linette, G.P.; Meyer, N.; Giguere, J.K.;Agarwala, S.S.(2015).Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med, 372, 2006 – 2017.

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Butler, M. O., Hill, A. G., Marquez-Rodas, I., Haanen, J. B. A. G.,Bas, T., van Dijck, W., Larkin, J., & Hodi, F. S. (2021). CheckMate 067: 6. 5-year outcomes in patients (pts) with advanced melanoma. Journal ofClinical Oncology, 39 (15_suppl), 9506 – 9506.

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., ... & Wolchok, J. D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364 (26), 2517 - 2526.

Zhang N, Xiao X. (2021). Integrative medicine in the era of cancer immuno therapy: challenges and opportunities. J Integr Med, 19 (4): 291 – 4.

Zhang Y, Wei Y, Jiang S, et al. (2022). Traditional Chinese medicine CFF-1 exerts a potent anti-tumor immunity tohinder tumor growth and metastasis in prostate cancer through EGFR/JAK1/STAT3pathway toinhibit PD-1/ PD-L1 checkpoint signalling. Phytomedicine, 99: 153939.

Chang, C. Y., Park, H., Malone, D. C., Wang, C.Y., Wilson, D. L., Yeh, Y. M., ... & Lo-Ciganic, W.H. (2020). Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis. JAMA network open, 3 (3), e201611 - e201611.

Hoejberg, L.; Bastholt, L.; Schmidt, H. (2012). Interleukin-6 and melanoma. Melanoma Res, 22, 327 – 333. [PubMed].

Sabbatino, F., Liguori, L., Pepe, S., &Ferrone, S. (2022). Immune checkpoint inhibitors for the treatment of melanoma. Expert opinion on biological therapy, 22 (5), 563 – 576.

Buder-Bakhaya, K., & Hassel, J. C. (2018). Biomarkers for clinical benefit of immune checkpoint inhibitor treatment—a review from the melanoma perspective and beyond. Frontiers in immunology, 9, 1474.

Downloads

Published

29-12-2023